ArticleJournal of gastroenterology2024
Publisher Correction: CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
Masayuki Ueno et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.